Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Shares of Novavax Inc. NVAX shed 2.97% to $6.20 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 3.07% to 16,307.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...